|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Celgene
|
|
gptkbp:activities
|
immunomodulatory agent
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Revlimid
|
|
gptkbp:can_be_used_with
|
gptkb:carfilzomib
gptkb:bortezomib
gptkb:cyclophosphamide
gptkb:rituximab
gptkb:dexamethasone
lenalidomide and dexamethasone
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
history of thrombosis
|
|
gptkbp:developed_by
|
gptkb:Celgene_Corporation
|
|
gptkbp:discovered_by
|
2000s
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lenalidomide
|
|
gptkbp:ingredients
|
C13 H13 N3 O3
|
|
gptkbp:interacts_with
|
gptkb:warfarin
gptkb:dexamethasone
other immunosuppressants
dexlansoprazole
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
L04 A X03
|
|
gptkbp:is_available_in
|
various dosages
|
|
gptkbp:is_used_for
|
gptkb:myelodysplastic_syndromes
gptkb:healthcare_organization
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
oral capsule
|
|
gptkbp:produced_by
|
gptkb:chemical_compound
|
|
gptkbp:related_to
|
gptkb:thalidomide
gptkb:pomalidomide
|
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
diarrhea
rash
constipation
thrombocytopenia
neutropenia
|
|
gptkbp:type_of
|
191732-72-6
|